Atara Biotherapeutics, Inc. (ATRA) to Post Q3 2017 Earnings of ($1.10) Per Share, Jefferies Group Forecasts
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) – Research analysts at Jefferies Group issued their Q3 2017 earnings per share estimates for shares of Atara Biotherapeutics in a report released on Tuesday. Jefferies Group analyst M. Raycroft anticipates that the biotechnology company will post earnings per share of ($1.10) for the quarter. Jefferies Group currently has a “Buy” rating and a $30.00 target price on the stock. Jefferies Group also issued estimates for Atara Biotherapeutics’ Q4 2017 earnings at ($1.32) EPS, FY2017 earnings at ($4.24) EPS, FY2018 earnings at ($5.25) EPS, FY2019 earnings at ($5.65) EPS, FY2020 earnings at ($5.25) EPS and FY2021 earnings at ($4.17) EPS.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.89) by $0.05. COPYRIGHT VIOLATION WARNING: This news story was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/10/atara-biotherapeutics-inc-atra-to-post-q3-2017-earnings-of-1-10-per-share-jefferies-group-forecasts.html.
ATRA has been the topic of a number of other reports. Canaccord Genuity restated a “buy” rating and issued a $47.00 price objective on shares of Atara Biotherapeutics in a research note on Friday, April 21st. William Blair reaffirmed an “outperform” rating on shares of Atara Biotherapeutics in a report on Monday, June 26th. Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 9th. Finally, ValuEngine downgraded shares of Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $25.75.
Shares of Atara Biotherapeutics (NASDAQ:ATRA) opened at 14.50 on Thursday. Atara Biotherapeutics has a 1-year low of $11.80 and a 1-year high of $23.40. The stock’s 50 day moving average is $15.02 and its 200 day moving average is $15.89. The stock’s market capitalization is $422.08 million.
Several hedge funds have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Atara Biotherapeutics during the first quarter valued at $132,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of Atara Biotherapeutics during the first quarter valued at $185,000. State of Wisconsin Investment Board purchased a new stake in shares of Atara Biotherapeutics during the second quarter valued at $252,000. American International Group Inc. increased its stake in shares of Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 948 shares during the last quarter. Finally, IndexIQ Advisors LLC purchased a new stake in shares of Atara Biotherapeutics during the second quarter valued at $323,000. 81.50% of the stock is currently owned by institutional investors and hedge funds.
In other news, CEO Isaac E. Ciechanover sold 2,800 shares of Atara Biotherapeutics stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $16.94, for a total value of $47,432.00. Following the sale, the chief executive officer now owns 731,859 shares of the company’s stock, valued at $12,397,691.46. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gad Soffer sold 12,674 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $15.16, for a total transaction of $192,137.84. Following the completion of the sale, the executive vice president now directly owns 259,527 shares in the company, valued at approximately $3,934,429.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,308 shares of company stock worth $797,382. Insiders own 16.10% of the company’s stock.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.